3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
3
Sarcoma, Endometrial Stromal
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Advanced Breast Cancer
1
Adenosarcoma of the uterus
1
Interventions
pembrolizumab
39
Bevacizumab
25
Cyclophosphamide
23
Blood Specimen Collection
19
Standard of Care
17
Nivolumab
17
Carboplatin
17
Paclitaxel
15
Exercise
15
Gemcitabine
14
atezolizumab
13
Pemetrexed
13
Cisplatin
13
Radiotherapy
11
Fluorouracil
11
Doxorubicin
11
Cetuximab
10
130-nm albumin-bound paclitaxel
10
durvalumab
9
Rituximab
9
Oxaliplatin
9
Magnetic Resonance Spectroscopy
9
Leucovorin
9
Docetaxel
9
Biopsy
9
abemaciclib
8
Temozolomide
8
Surveys and Questionnaires
8
Prednisone
8
olaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
RAD1901
×
90 days
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled